

=> d his

(FILE 'HOME' ENTERED AT 14:56:12 ON 15 DEC 2004)

FILE 'MEDLINE' ENTERED AT 14:56:30 ON 15 DEC 2004

L1 4 S BK4  
L2 0 S SLO ION CHANNEL  
L3 847 S SLO  
L4 0 S L1 (L) L3  
L5 0 S BK BETA 4  
L6 30 S BK (W) (BETA OR B) AND.4  
L7 36653 S ION CHANNEL  
L8 0 S L6 (L) L7  
L9 0 S L7 AND L6

FILE 'CAPLUS, USPATFULL, MEDLINE, BIOSIS' ENTERED AT 15:01:44 ON 15 DEC 2004

L10 4 S BK BETA 4  
L11 5 S BK (W) (BETA OR B) (W)4  
L12 4 DUP REM L11 (1 DUPLICATE REMOVED)

L12 ANSWER 1 OF 4 USPATFULL on STN  
 AN 2004:159292 USPATFULL  
 TI Use of inhibitors of the cellular Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE) for preparing a medicament for normalizing serum lipids  
 IN Lang, Hans Jochen, Hofheim, GERMANY, FEDERAL REPUBLIC OF  
 Jansen, Hans-Willi, Niederhausen, GERMANY, FEDERAL REPUBLIC OF  
 Schwark, Jan-Robert, Kelkheim, GERMANY, FEDERAL REPUBLIC OF  
 Kleemann, Heinz-Werner, Bischofsheim, GERMANY, FEDERAL REPUBLIC OF  
 Jung, Oliver, Lahnau, GERMANY, FEDERAL REPUBLIC OF  
 Schafer, Hans-Ludwig, Hochheim, GERMANY, FEDERAL REPUBLIC OF  
 Linz, Wolfgang, Mainz, GERMANY, FEDERAL REPUBLIC OF  
 Kramer, Werner, Mainz-Laubenheim, GERMANY, FEDERAL REPUBLIC OF  
 Scholkens, Bernward, Kelkheim, GERMANY, FEDERAL REPUBLIC OF  
 Falk, Eugen, Frankfurt, GERMANY, FEDERAL REPUBLIC OF  
 PA Hoechst Aktiengesellschaft (non-U.S. corporation)  
 PI US 2004122096 A1 20040624  
 AI US 2003-680275 A1 20031008 (10)  
 RLI Continuation of Ser. No. US 2000-689692, filed on 13 Oct 2000, ABANDONED  
 Continuation of Ser. No. US 1998-194749, filed on 3 Dec 1998, ABANDONED  
 A 371 of International Ser. No. WO 1997-EP2548, filed on 20 May 1997,  
 UNKNOWN  
 PRAI DE 1996-19622222 19960603  
 DE 1997-19712636 19970326  
 DT Utility  
 FS APPLICATION  
 LN.CNT 8831  
 INCL INCLM: 514/560.000  
 NCL NCLM: 514/560.000  
 IC [7]  
 ICM: A61K031-20  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 112 1-4 ti au py so abs

L12 ANSWER 1 OF 4 USPATFULL on STN  
 TI Use of inhibitors of the cellular Na<sup>+</sup>/H<sup>+</sup> exchanger (NHE) for preparing a medicament for normalizing serum lipids  
 IN Lang, Hans Jochen, Hofheim, GERMANY, FEDERAL REPUBLIC OF  
 Jansen, Hans-Willi, Niederhausen, GERMANY, FEDERAL REPUBLIC OF  
 Schwark, Jan-Robert, Kelkheim, GERMANY, FEDERAL REPUBLIC OF  
 Kleemann, Heinz-Werner, Bischofsheim, GERMANY, FEDERAL REPUBLIC OF  
 Jung, Oliver, Lahnau, GERMANY, FEDERAL REPUBLIC OF  
 Schafer, Hans-Ludwig, Hochheim, GERMANY, FEDERAL REPUBLIC OF  
 Linz, Wolfgang, Mainz, GERMANY, FEDERAL REPUBLIC OF  
 Kramer, Werner, Mainz-Laubenheim, GERMANY, FEDERAL REPUBLIC OF  
 Scholkens, Bernward, Kelkheim, GERMANY, FEDERAL REPUBLIC OF  
 Falk, Eugen, Frankfurt, GERMANY, FEDERAL REPUBLIC OF  
 AB Use of inhibitors of cellular Na<sup>sup.</sup>+/H<sup>sup.</sup>+/H<sup>sup.</sup> exchanger (NHE) for the production of a medicament for the normalization of serum lipids  
  
 The active compounds identified as inhibitors of the cellular Na<sup>sup.</sup>+/H<sup>sup.</sup>+/H<sup>sup.</sup> exchanger (NHE) are used for the production of a medicament for the normalization of serum lipids.

They are used for the production of a medicament for lowering the blood lipid level and illnesses caused thereby, as well as of endothelial dysfunction syndrome and illnesses caused thereby.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 4 USPATFULL on STN DUPLICATE 1  
TI Beta subunits of Slo family potassium channels  
IN Jegla, Timothy J., Durham, NC, United States  
Wickenden, Alan, Cary, NC, United States  
Liu, Yi, Cary, NC, United States  
AB The invention provides isolated nucleic acid and amino acid sequences of BK beta 2, BK beta 3, and **BK beta 4**, antibodies to the BK beta subunits, methods of detecting the BK beta subunits, methods of screening for modulators of Slo potassium channels comprising BK beta subunits, and kits for screening for activators and inhibitors of the Slo family potassium channels comprising BK beta subunits.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
TI BK $\beta$  subunits of slo family potassium channels and cDNAs encoding them  
IN Jegla, Timothy James; Wickenden, Alan; Liu, Yi  
PY 2000  
2000  
2001  
2002  
2003  
SO PCT Int. Appl., 84 pp.  
CODEN: PIXXD2  
AB The invention provides isolated nucleic acid and amino acid sequences of BK $\beta$ 2, BK $\beta$ 3, and **BK.beta.4**, antibodies to the proteins, methods of detecting them, methods of screening for modulators of Slo potassium channels comprising BK beta subunits, and kits for screening for activators and inhibitors of the Slo family potassium channels comprising BK beta subunits.

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN  
TI hKCNMB3 and hKCNMB4, cloning and characterization of two members of the large-conductance calcium-activated potassium channel  $\beta$  subunit family  
AU Behrens, R.; Nolting, A.; Reimann, F.; Schwarz, M.; Waldschutz, R.; Pongs, O.  
PY 2000  
SO FEBS Letters (2000), 474(1), 99-106  
CODEN: FEBLAL; ISSN: 0014-5793  
AB We cloned two  $\beta$  subunits of large-conductance calcium-activated potassium (BK) channels, hKCNMB3 (BK $\beta$ 1) and hKCNMB4 (**BK.beta.4**). Profiling mRNA expression showed that hKCNMB3 expression is enriched in testis and hKCNMB4 expression is very prominent in brain. We coexpressed BK channel  $\alpha$  (BK $\alpha$ ) and **BK.beta.4** subunits in vitro in CHO cells. We compared BK $\alpha$ / $\beta$ 4 mediated currents with those of smooth muscle BK $\alpha$ / $\beta$ 1 channels. **BK.beta.4** slowed activation kinetics more significantly, led to a steeper apparent calcium sensitivity, and shifted the voltage range of BK current activation to more neg. potentials than BK $\beta$ 1. BK $\alpha$ / $\beta$ 4 channels were not blocked by 100 nM charybdotoxin or iberiotoxin, and were activated by 17 $\beta$ -estradiol.